Bausch & Lomb Inc. and Nicox SA filed a federal lawsuit in New Jersey alleging a generic version of Vyzulta proposed by Gland Pharma Ltd. infringes four patents for the intraocular pressure-reducing eye drops.
Vyzulta, an ophthalmic solution with an active ingredient of latanoprostene bunod, is used to reduce such pressure in patients with open-angle glaucoma or ocular hypertension, according to a complaint filed Thursday in the US District Court for the District of New Jersey.
Gland is a unit of
Bausch & Lomb Ireland Ltd. exclusively licenses the patents from Nicox, with Bausch & ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.